Skip to content
Screener

Gyre Therapeutics, Inc. GYRE Gyre Pharmaceuticals — Cost of Goods Sold

Other segment segments

Gyre
$0

Similar metrics at other companies

Opko Health logo
OPKPharmaceutical — Cost of Goods Sold
$25.1M+0.3%
Cal-Maine Foods logo
CALMPrepared Foods — Cost of Goods Sold
$46.34M+4,009%
Flexible Solutions International logo
FSICost of Goods Sold
$6.41M+16.0%
Recursion Pharmaceuticals, Inc. logo
RXRXCost of Goods Sold
$11.49M-43.0%
Owens Corning logo
OCCost of Goods Sold
$1.96B+3.9%
Dynatrace logo
DTCost of Goods Sold
$103.45M+21.4%

Other financials

Income statement

See full
Revenue$29.1M-2.1%
Gross profit$26.9M-5.9%
Operating income-$14.4M-541%
Net income-$11.7M-471%
EPS (diluted)-$0.12-300%

Balance sheet

See full
Cash & equivalents$43.3M+18.6%
Total debt$3.4M+145%
Total equity$107.9M+17.3%
Total assets$199.3M+30.5%

Cash flow

See full
Operating cash flow-$16.7M-124%
CapEx$262.0K-21.8%
Free cash flow-$17.0M-118%

Valuation

See full
Market cap$712.55M+11.2%
Enterprise value$672.68M+11.0%
P/S-0.1×

Profitability

See full
Gross margin94.3%-1.7pp
Operating margin-14%-18.7pp
Net margin-13.4%-15.1pp
FCF margin-5.1%

Returns & leverage

See full
Return on equity-16%-18.3pp
Debt / equity0.0×
Current ratio4.3×-1.1×

Where this comes from

Reported directly by Gyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 5:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-340448
Line itemGyre PharmaceuticalsGyreTotal
Revenues$29,097$8$29,105
Operating expenses
Cost of revenues2,2092,209
Selling and marketing13,75413,754
Research and development9,6974,60314,300
Research and development - related parties4,8364,836
General and administrative4,2683,5947,862
Transaction costs502502

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Gyre Therapeutics, Inc.'s gyre pharmaceuticals — cost of goods sold?
Gyre Therapeutics, Inc. (GYRE) reported gyre pharmaceuticals — cost of goods sold of $2.21M in Q2 2026.
How has Gyre Therapeutics, Inc.'s gyre pharmaceuticals — cost of goods sold changed year-over-year?
Gyre Therapeutics, Inc.'s gyre pharmaceuticals — cost of goods sold increased by 91.9% year-over-year, from $1.15M to $2.21M.
What is the long-term trend for Gyre Therapeutics, Inc.'s gyre pharmaceuticals — cost of goods sold?
Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s gyre pharmaceuticals — cost of goods sold has grown at a 8.1% compound annual growth rate (CAGR), from $4.64M to $5.42M.
What does gyre pharmaceuticals — cost of goods sold mean?
This reflects the direct costs attributable to the production and delivery of the pharmaceutical products sold by the segment. Monitoring this metric is essential for evaluating the segment's production efficiency and gross margin potential.

Ask your AI about Gyre Therapeutics, Inc.'s gyre pharmaceuticals — cost of goods sold.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude